NAV

4-(Acetylamino)-3-Guanidinobenzoic Acid

Identification

Generic Name
4-(Acetylamino)-3-Guanidinobenzoic Acid
DrugBank Accession Number
DB03342
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 238.2432
Monoisotopic: 238.106590334
Chemical Formula
C10H14N4O3
Synonyms
Not Available
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UNeuraminidaseNot AvailableInfluenza B virus (strain B/Lee/1940)
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as guanidinobenzoic acids. These are aromatic compounds containing a guanidine group linked to the benzene ring of a benzoic acid.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Guanidinobenzoic acids
Alternative Parents
Acylaminobenzoic acid and derivatives / Acetanilides / N-acetylarylamines / Benzoic acids / Phenylalkylamines / Benzoyl derivatives / Secondary alkylarylamines / Acetamides / Secondary carboxylic acid amides / Orthocarboxylic acid derivatives
show 9 more
Substituents
Acetamide / Acetanilide / Acylaminobenzoic acid or derivatives / Amine / Amino acid / Amino acid or derivatives / Anilide / Aromatic homomonocyclic compound / Benzoic acid / Benzoyl
show 22 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
V02KF5948M
CAS number
Not Available
InChI Key
HIXHCUDMJUERSJ-UHFFFAOYSA-N
InChI
InChI=1S/C10H14N4O3/c1-5(15)13-7-3-2-6(9(16)17)4-8(7)14-10(11)12/h2-4,10,14H,11-12H2,1H3,(H,13,15)(H,16,17)
IUPAC Name
3-[(diaminomethyl)amino]-4-acetamidobenzoic acid
SMILES
CC(=O)NC1=CC=C(C=C1NC(N)N)C(O)=O

References

General References
Not Available
PubChem Compound
3364666
PubChem Substance
46505537
ChemSpider
2610454
ZINC
ZINC000019328706
PDBe Ligand
ST4
PDB Entries
1inf

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.28 mg/mLALOGPS
logP-2.3ALOGPS
logP-1.8Chemaxon
logS-2.3ALOGPS
pKa (Strongest Acidic)4.78Chemaxon
pKa (Strongest Basic)5.91Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count5Chemaxon
Polar Surface Area130.47 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity64.51 m3·mol-1Chemaxon
Polarizability23.79 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.8103
Blood Brain Barrier+0.8244
Caco-2 permeable-0.5837
P-glycoprotein substrateNon-substrate0.6397
P-glycoprotein inhibitor INon-inhibitor0.9758
P-glycoprotein inhibitor IINon-inhibitor0.9965
Renal organic cation transporterNon-inhibitor0.9614
CYP450 2C9 substrateNon-substrate0.7869
CYP450 2D6 substrateNon-substrate0.8497
CYP450 3A4 substrateNon-substrate0.8045
CYP450 1A2 substrateNon-inhibitor0.9243
CYP450 2C9 inhibitorNon-inhibitor0.9101
CYP450 2D6 inhibitorNon-inhibitor0.9734
CYP450 2C19 inhibitorNon-inhibitor0.9573
CYP450 3A4 inhibitorNon-inhibitor0.9783
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.995
Ames testNon AMES toxic0.5256
CarcinogenicityNon-carcinogens0.8064
BiodegradationReady biodegradable0.5544
Rat acute toxicity2.0126 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9907
hERG inhibition (predictor II)Non-inhibitor0.9809
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0002-3900000000-2e249471d31406382dd1
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-00dr-0090000000-e84b3deeec461ee905de
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00g0-0980000000-de7d6952468ee0e114bf
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-05fr-0290000000-3f65e378bf2aa0bd991b
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-002b-0900000000-9042d924517a191a94b4
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-03g0-0910000000-317787dc3cfd21c909de
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-4900000000-67aa449b662032644548
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-146.81041
predicted
DeepCCS 1.0 (2019)
[M+H]+149.1684
predicted
DeepCCS 1.0 (2019)
[M+Na]+155.45982
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Neuraminidase
Kind
Protein
Organism
Influenza B virus (strain B/Lee/1940)
Pharmacological action
Unknown
General Function
Metal ion binding
Specific Function
Catalyzes the removal of terminal sialic acid residues from viral and cellular glycoconjugates. Cleaves off the terminal sialic acids on the glycosylated HA during virus budding to facilitate virus...
Gene Name
NA
Uniprot ID
P03474
Uniprot Name
Neuraminidase
Molecular Weight
51441.185 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52